GlassScriptPhysician profile
Annie Celeste Hart
NPI 1144703257
$4,945.40
in general payments reported to CMS, 2019-2025
33 companies · $707 in 2025
The $707 reported for 2025 was more than what 77% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $529 · 2022: $1,264 · 2023: $1,090 · 2024: $1,355 · 2025: $707.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,152.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,151.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,349.24 | 2021-2025 | Fasenra, Farxiga, Breztri |
| Abbvie INC. | $1,040.80 | 2021-2025 | |
| Novo Nordisk INC | $620.73 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $288.18 | 2021-2025 | |
| Lilly USA, LLC | $219.14 | 2022-2024 | Mounjaro, Zepbound |
| Sanofi-Aventis U.S. LLC | $188.05 | 2022-2025 | |
| Boston Scientific Corporation | $97.19 | 2021-2025 | General - Pain Management |
| Novartis Pharmaceuticals Corporation | $85.86 | 2022-2025 | |
| Nevro Corp. | $83.58 | 2021-2023 | Senza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $81.56 | 2021-2025 | Jardiance |
| Amgen INC. | $78.79 | 2022-2024 | Repatha, Otezla |
| Abbott Laboratories | $64.70 | 2023-2025 | Proclaim, Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $62.58 | 2023-2025 | Shingrix, Trelegy Ellipta |
| Daiichi Sankyo INC. | $55.11 | 2023-2025 | Injectafer |
| Astellas Pharma US INC | $54.96 | 2023-2024 | Veozah, Myrbetriq |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $54.05 | 2025 | Auvelity |
| Bayer Healthcare Pharmaceuticals INC. | $52.95 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $51.45 | 2022-2024 | Gardasil 9, Capvaxive, Gardasil |
| Sanofi Pasteur INC. | $48.44 | 2023-2025 | |
| Sumitomo Pharma America, INC. | $45.14 | 2024 | Gemtesa |
| Dexcom, INC. | $37.25 | 2024-2025 | Dexcom G6 Transmitter |
| Kestra Medical Technology Services, INC. | $35.94 | 2024-2025 | Assure Wcd |
| Biohaven Pharmaceutical Holding Company LTD. | $31.44 | 2022 | |
| Inspire Medical Systems, INC. | $29.82 | 2024 | Inspire |
| Biogen, INC. | $28.22 | 2021-2023 | Spinraza |
| Teva Pharmaceuticals USA, INC. | $25.03 | 2025 | Ajovy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $24.80 | 2025 | Caplyta |
| Atricure, INC. | $21.48 | 2024 | |
| Verity Pharmaceuticals INC. | $21.16 | 2024 | Tlando |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.58 | 2025 | Xifaxan |
| Teleflex LLC | $17.40 | 2022 | |
| Lucid Diagnostics INC. | $16.76 | 2022 | |
| Sunovion Pharmaceuticals INC. | $14.02 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Annie Hart listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.